// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























486 Abstracts

OUTCOMES OF COMBINED, CONCURRENT, AND SEQUENTIAL INTERVENTIONAL THERAPY FOR HUGE HEPATOCELLULAR CARCINOMA

Xiao An - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

iodine-125

THE VALUE OF GOLGI PROTEIN 73 AS A MARKER FOR DIFFERENTIATING BETWEEN SOLID BENIGN AND MALIGNANT LIVER TUMOURS

Mirelle Broker - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

SORAFENIB AND CAPECITABINE FOR HEPATOCELLULAR CARCINOMA (HCC), A PHASE II TRIAL

Yehuda Patt - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

Capecitabine

VERY HIGH ALPHA-FETOPROTEIN (AFP): A POOR PROGNOSTIC INDICATOR IN HEPATOCELLULAR CARCINOMA IN THE MODERN ERA

Shweta Gupta - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Alfa-fetoprotein

REDISCOVERING KOJIR-S CLASSIFICATION: THE IMPORTANCE OF SMALL TUMOR EVALUATION IN HCC

Martins Aline M - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

FETOPROTEIN (AFP) RESPONSE BY GC33 CORRELATES TO PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Y. Jin - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

GC33

Perils of Peutz-Jegher Syndrome: Recurrent Ovarian Sertoli-Leydig Cell Tumor in a Pediatric Patient

Edward John Bellfield - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Sertoli-Leydig cell tumors

Alora

Struma Ovarii - a Management Dilemma

Amrita Kaur Dhillon - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyslipidemia

N/A

EVALUATION OF SERUM FETUIN-A AND APELIN LEVELS IN FAMILIAL MEDITERRANEAN FEVER (FMF) PATIENTS AND HEALTHY SUBJECTS

A. Sahin - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Familial Mediterranean fever

Fibrinogen (IV)

Evaluation of Serum Fetuin-A and Apelin Levels in Familial Mediterranean Fever (FMF) Patients and Healthy Subjects

A. Sahin - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Familial Mediterranean fever

Fibrinogen (IV)

Markers Expression Is Affected by TNF-Inhibitors and Tocilizumab Treatment in Rheumatoid Arthritis

A. Sahin - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

RECRUITMENT DIFFICULTY FOR UNAFFECTED RHEUMATOID ARTHRITIS RELATIVES DUE TO MISPLACED GUILT?

F. Cornelis - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PULMONARY FUNCTION AND COMPUTED TOMOGRAPHY IMAGING IN PRIMARY Sjogren's Syndrome AND RISK FACTORS FOR LUNG COMPLICATION IN A LARGE COHORT

H. Gao - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic interstitial pneumonias

N/A

Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).

Petra Prins - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Josep M Llovet - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ramucirumab

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).

Darren R. Feldman - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ifosfamide

Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.

Allison Frances O'Neill - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma.

Michael J Nisiewicz - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alfa-fetoprotein

National society-supplied patient materials on prostate cancer screening for the general public:A readability analysis.

Michael Kevin Rooney - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

ET140202 t-cells: Anovel therapy targeting AFP/MHC complex, that is both safe and effective in treating metastatic hepatocellular carcinoma.

Chang Liu - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved